Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LupinNSE:LUPIN -0.72%92 EV-to-EBIT is 12.21 as of Sep. 21, 2026, which is 51% below its 10-year median of 25.11. GuruFocus rates NSE:LUPIN with a GF Score™ of 92/100 and a GF Value™ of ₹2,592.77 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 682 Drug Manufacturers companies, Lupin ranks better than 62.17% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lupin's Enterprise Value is ₹968,031 Mil.
Lupin's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was ₹79,268 Mil. Therefore, Lupin's EV-to-EBIT for today is 12.21.
The historical rank and industry rank for Lupin's EV-to-EBIT or its related term are showing as below:
NSE:LUPIN'
s EV-to-EBIT Range Over the Past 10 Years
Min: -144.22 Med: 25.11 Max: 160.51
Current: 12.21
During the past 13 years, the highest EV-to-EBIT of Lupin was 160.51. The lowest was -144.22. And the median was 25.11.
NSE:LUPIN's EV-to-EBIT is ranked better than 62.17% of 682
companies
in the Drug Manufacturers industry
Industry Median: 16.08
vs NSE:LUPIN: 12.21
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lupin's Enterprise Value for the quarter that ended in Jun. 2026 was ₹ Mil.
Lupin's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹79,268 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lupin EV-to-EBIT Related Terms
Lupin EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Lupin's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lupin's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lupin EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lupin's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lupin's EV-to-EBIT falls into.
Lupin's current Enterprise Value is ₹968,031 Mil.
Lupin's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹79,268 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lupin (NSE:LUPIN) has a EV-to-EBIT of 12.21 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lupin and its competitors. This is 51% below median its historical median of 25.11. According to the industry distribution chart, Lupin ranks #258 out of 682 companies in the Drug Manufacturers industry, placing it in the top 37.8%.
Is Lupin's EV-to-EBIT too high?
Lupin's current EV-to-EBIT of 12.21 is 51% below median its 10-year median of 25.11. The Drug Manufacturers industry median EV-to-EBIT is 16.08. Lupin's value of 12.21 is 24.1% below this industry median. Based on the distribution chart, Lupin ranks #258 out of 682 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lupin has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lupin's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lupin ranks #258 out of 682 companies for EV-to-EBIT. This puts Lupin in the upper half of its industry. The industry median EV-to-EBIT is 16.08. Lupin's value of 12.21 is 24.1% below this benchmark. While the company's 10-year median is 25.11 vs. the industry median of 16.08, Lupin has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.08, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lupin's current EV-to-EBIT of 12.21 is 24.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lupin and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lupin's current EV-to-EBIT is 12.21, which is 51% below median its own 10-year median of 25.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lupin stock overvalued right now?
Based on GuruFocus' analysis, Lupin (NSE:LUPIN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,592.77, compared to a current price of ₹2,083.00 — trading 19.7% below its estimated fair value. The current EV-to-EBIT is 12.21, which is 51% below median its 10-year median of 25.11 and 24.1% below the Drug Manufacturers industry median of 16.08. Lupin's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Lupin (NSE:LUPIN), the current EV-to-EBIT is 12.21 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lupin (NSE:LUPIN) Overvalued in 2026?
Based on GuruFocus' analysis, Lupin stock appears to be undervalued.
The current stock price of ₹2,083.00 is trading 19.7% below its estimated GF Value™ of ₹2,592.77.
GuruFocus considers Lupin to be Modestly Undervalued.
Key valuation signals for NSE:LUPIN:
EV-to-EBIT: 12.21 (51% below median its 10-year median of 25.11)
GF Value™: ₹2,592.77 vs. price of ₹2,083.00 (19.7% below fair value)
Industry Position: 24.1% below the Drug Manufacturers median (#258 of 682)
No single metric tells the full story. See the NSE:LUPIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.
92GF Score
Get the complete analysis for NSE:LUPIN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LUPIN has been successfully added to your 
